Home  /  Resource Library  /  Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged over 60 Years

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged over 60 Years

ASH 2019: Results of a phase II study investigating Brentuximab Vedotin combined with Nivolumab for first line treatment of elderly patients with Hodgkin lymphoma.